Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
LTRN 
Lantern Pharma Inc (LTRN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: LTRN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22
1 Year Target Price $22
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.83% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 43.06M USD | Price to earnings Ratio - | 1Y Target Price 22 |
Price to earnings Ratio - | 1Y Target Price 22 | ||
Volume (30-day avg) 2 | Beta 1.6 | 52 Weeks Range 2.55 - 6.12 | Updated Date 12/9/2025 |
52 Weeks Range 2.55 - 6.12 | Updated Date 12/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -55.99% | Return on Equity (TTM) -104.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 29672964 | Price to Sales(TTM) - |
Enterprise Value 29672964 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.21 | Shares Outstanding 11184423 | Shares Floating 8587400 |
Shares Outstanding 11184423 | Shares Floating 8587400 | ||
Percent Insiders 13.6 | Percent Institutions 20.54 |
Upturn AI SWOT
Lantern Pharma Inc
Company Overview
History and Background
Lantern Pharma Inc. was founded in 2013 and is a clinical-stage biopharmaceutical company leveraging its proprietary AI platform, RADR, to rescue, revitalize, and develop precision therapeutics for cancer. The company has built a portfolio of targeted therapies, aiming to personalize cancer treatment based on a patient's genetic profile.
Core Business Areas
- Drug Development: Focuses on developing and commercializing novel cancer therapies using its RADR AI platform to identify and validate drug candidates.
- AI Platform Licensing: Potentially licensing the RADR AI platform to other pharmaceutical companies for drug discovery and development.
Leadership and Structure
Panna Sharma is the President and CEO. The company has a board of directors overseeing strategy and governance, and a scientific advisory board guiding research and development.
Top Products and Market Share
Key Offerings
- LP-100 (Onapristone extended release): A drug candidate targeting AR-positive cancers, currently in clinical development. No significant market share information available. Competitors include companies developing similar AR-targeting therapies such as ARV-110 (Orgovyx) from Arvinas in prostate cancer.
- LP-300: A drug candidate being developed for never smokers with advanced lung cancer. No significant market share information available. Competitors include pharmaceutical companies developing treatments for non-small cell lung cancer, such as AstraZeneca (Tagrisso) and Roche (Tecentriq).
- RADR AI Platform: A proprietary AI platform used to predict drug response and identify patient populations likely to benefit from specific therapies. No direct revenue figures available. Competitors include other AI-driven drug discovery companies like Schrodinger and Exscientia.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The market is driven by increasing cancer incidence, technological advancements in drug discovery, and growing demand for personalized medicine.
Positioning
Lantern Pharma is positioned as a precision oncology company leveraging AI to accelerate drug development and personalize cancer treatment. Its competitive advantage lies in its RADR AI platform and its focus on rescuing and revitalizing previously abandoned drug candidates.
Total Addressable Market (TAM)
The global oncology market is expected to reach hundreds of billions of dollars. Lantern Pharma is positioned to address niche markets within oncology where its targeted therapies have the potential to demonstrate significant clinical benefit. Actual TAM depends on the specific cancer types targeted and market penetration achieved.
Upturn SWOT Analysis
Strengths
- Proprietary RADR AI platform
- Focus on precision oncology
- Experienced management team
- Portfolio of targeted therapies in development
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- Competition from larger pharmaceutical companies
- Early stage development of its pipeline
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of RADR AI platform capabilities
- Acquisition of new drug candidates
- Successful clinical trial results leading to regulatory approvals
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from new therapies
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- ARVN
- AZN
- RHHBY
- CRSP
- EDIT
Competitive Landscape
Lantern Pharma faces intense competition from established pharmaceutical companies with greater resources and more advanced drug pipelines. Its advantage lies in its AI-driven approach and focus on precision oncology, which could lead to more efficient drug development and personalized treatment strategies.
Growth Trajectory and Initiatives
Historical Growth: Requires access to historical financial data.
Future Projections: Requires access to analyst estimates and company guidance.
Recent Initiatives: Focus on advancing clinical trials for LP-100 and LP-300, expanding the capabilities of the RADR AI platform, and exploring potential partnerships.
Summary
Lantern Pharma is a clinical-stage biopharmaceutical company with a promising AI-driven approach to drug development. While its early-stage pipeline and limited financial resources pose challenges, the RADR AI platform offers a potential competitive advantage. Successful clinical trial outcomes and strategic partnerships are crucial for its future growth. The company will need to carefully manage its cash burn and navigate the competitive landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Lantern Pharma Inc. website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be subject to change. Market share data are estimates and may not be precise. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lantern Pharma Inc
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2020-06-11 | President, CEO & Director Mr. Panna Sharma | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | Website https://www.lanternpharma.com |
Full time employees 24 | Website https://www.lanternpharma.com | ||
Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.